The early results of Van den Berghe et al. led to the widespread use of continuous insulin therapy for glucose control.
Exclusion criteria were: neutropenia (<1000/mm), burns, myasthenia gravis, pregnancy, body mass index (BMI) >40 kg/m, chronic renal failure requiring dialysis (HD) or the use of continuous renal replacement therapy (CRRT) at the onset of therapy.
Continuous renal replacement therapy was particularly helpful in controlling the patient's life-threatening metabolic derangements; hepatic replacement therapy was of uncertain benefit and interfered with the optimal use of continuous renal replacement therapy.
The use of (continuous) renal replacement therapy may lead to hypophosphatemia when low-phosphate replacement solution and dialysate are used.
Secondary outcomes included hospital and ICU length of stay (LOS), hospital mortality, use of continuous renal replacement therapy (CRRT).
There have been case reports on the use of continuous renal replacement therapy (CRRT) for induction and maintenance of hypothermia [ 52, 53].
4924 consecutive unselected unilateral primary THA and TKAs in patients ≥18 years with no preoperative use of continuous 'potent' anticoagulative therapy (vitamin K antagonists).
Additional factors predisposing to hypoglycemia have been identified that are more likely to be modifiable including adjustments to nutritional support without concomitant adjustment to insulin administration, use of vasoactive medications, and use of continuous renal replacement therapy.
Longer term outcomes to be followed include duration of mechanical ventilation, use of continuous renal replacement therapy, use of extracorporeal assist devices such as extracorporeal membrane oxygenation (ECMO) or ventricular assist devices (VADs), ICU length of stay, and mortality (Day 30 follow up).
Overnight use of continuous low-level heatwrap therapy for relief of low back pain.
